LINCOLN PHARMA LTD chart

Last update: 2022-06-03
Key statistics and financials
Revenue per share 235.74
Dividend & Yield1.50₹ (0.57%)
Beta 0.66
Market capitalization 5.78B
Operating cash flow 761.32M
ESG Scores unknown

Company description

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities -1.4M 72.28M 55.5M 145.93M
Total Cashflows From Investing Activities -181.88M -308.83M -642.27M -780.8M
Net Borrowings -276.78M -285.35M -45.54M 14.8M
Total Cash From Financing Activities -357.68M -377.59M -57.46M -25.56M
Change To Operating Activities 35.42M -7.43M 39.53M 170.6M
Issuance Of Stock
Net Income 487.1M 514.39M 622.24M 693.55M
Change In Cash -11.11M 67.74M -7.03M -45.04M
Effect Of Exchange Rate
Total Cash From Operating Activities 528.45M 754.15M 692.7M 761.32M
Depreciation 66M 71.95M 74.22M 80.88M
Change To Account Receivables -137.05M 190.16M -100.82M -31.15M
Other Cashflows From Financing Activities -50.91M -32.24M -11.91M -10.36M
Change To Netincome -14.48M 23.18M -7.18M -37.2M
Capital Expenditures -149.38M -76.91M -87.5M -455.25M

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development
Income Before Tax 621.95M 672.33M 837.21M 959.39M
Net Income 487.1M 514.39M 622.24M 693.55M
Selling General Administrative 660.06M 734.98M 756.64M 704.69M
Gross Profit 1.86B 2B 2.23B 2.54B
Ebit 608.2M 583.39M 798.01M 873.93M
Operating Income 608.2M 583.39M 798.01M 873.93M
Interest Expense -30.94M -14.97M -12.02M -14.51M
Income Tax Expense 134.56M 157.66M 214.71M 265.84M
Total Revenue 3.66B 3.86B 4.24B 4.72B
Cost Of Revenue 1.8B 1.86B 2.01B 2.19B
Total Other Income ExpenseNet 13.74M 88.94M 39.2M 85.47M
Net Income From Continuing Ops 487.39M 514.66M 622.5M 693.55M
Net Income Applicable To Common Shares 487.1M 514.39M 622.24M 693.55M

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 962.85M 759.17M 836.72M 1.01B
Total Stockholder Equity 2.69B 3.13B 3.75B 4.33B
Other Current Liabilities 43.21M 69.3M 105.29M 167.84M
Total Assets 3.66B 3.89B 4.59B 5.34B
Common Stock 200M 200M 200M 200.3M
Other Current Assets 361.35M 352.83M 358.02M 167.83M
Retained Earnings 1.84B 2.28B 2.91B
Treasury Stock 4.83M 215k 411k 4.13B
Cash 54.57M 122.31M 114.38M 188M
Total Current Liabilities 853.36M 655.83M 735.46M 904.86M
Other Stockholder Equity 4.83M 215k 411k 4.13B
Property, Plant, and Equipment 1.13B 1.13B 1.12B 1.48B
Total Current Assets 2.24B 2.48B 3.06B 3.53B
Net Tangible Assets 2.6B 3.03B 3.66B 4.32B
Net Receivables 1.27B 1.18B 1.31B 1.48B
Accounts Payable 440.15M 512.43M 567.92M 716.59M


Insider Transactions

Here are the insider transactions of stock shares related to LINCOLN PHARMA LTD:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Patel (Shardaben G)Other at price 4.16 per share.D2022-03-11Promoter31.4k
Patel (Shardaben G)D2022-03-11Promoter31.4k
Patel (Munjal M)Acquisition at price 4.00 per share.D2022-02-25Promoter20k
Patel (Munjal M)Acquisition at price 4.53 per share.D2021-12-21Director26k
Patel (Munjal M)Acquisition at price 4.72 per share.D2021-12-16Director34.5k
Patel (Ashish R)Acquisition at price 4.94 per share.D2021-12-09Additonal Director33.5k
Patel (Munjal M)Acquisition at price 4.84 per share.D2021-12-09Director16.5k
Patel (Ashish R)Acquisition at price 4.71 per share.D2021-12-06Additonal Director30k
Patel (Munjal M)Acquisition at price 4.71 per share.D2021-12-06Director32k
Patel (Anirudhh Hasmukhbhai)Acquisition at price 4.37 per share.D2021-12-01Promoter17.5k
Patel (Ashish R)Acquisition at price 4.37 per share.D2021-12-01Additonal Director10.5k
Patel (Jigar Hasmukhbhai)Acquisition at price 4.35 per share.D2021-12-01Promoter17.5k
Patel (Ashish R)Acquisition at price 4.34 per share.D2021-11-30Additonal Director25k
Patel (Anand Arvindbhai)Acquisition at price 4.39 per share.D2021-11-26Promoter31.75k
Patel (Anand Arvindbhai)Acquisition at price 4.54 per share.D2021-11-25Promoter18.25k
Patel (Ashish R)Acquisition at price 4.54 per share.D2021-11-24Additonal Director24k
Patel (Munjal M)Acquisition at price 4.33 per share.D2021-11-22Director19k
Patel (Ashish R)Acquisition at price 4.43 per share.D2021-11-18Promoter25k
Patel (Ashish R)Acquisition at price 5.13 per share.D2021-09-27Additonal Director31k
Patel (Mahendra G)Acquisition at price 5.17 per share.D2021-09-27Managing Director24k
Patel (Mahendra G)Acquisition at price 5.20 per share.D2021-09-21Managing Director35k
Patel (Mahendra G)Acquisition at price 5.20 per share.D2021-09-20Managing Director4.5k
Patel (Munjal M)Acquisition at price 5.18 per share.D2021-09-20Director35k
Patel (Munjal M)Acquisition at price 4.94 per share.D2021-09-08Director23.5k
Patel (Munjal M)Acquisition at price 4.89 per share.D2021-09-07Director50k
Patel (Ashish R)Acquisition at price 4.58 per share.D2021-09-06Additonal Director35k
Patel (Munjal M)Acquisition at price 4.60 per share.D2021-09-06Director25k
Patel (Ashish R)Acquisition at price 4.48 per share.D2021-09-01Additonal Director35k
Patel (Maheshbhai M)D2021-09-01Promoter30k
Patel (Munjal M)Acquisition at price 4.48 per share.D2021-09-01Director30k
Patel (Ashish R)Acquisition at price 4.42 per share.D2021-08-25Promoter35k
Patel (Munjal M)Acquisition at price 4.38 per share.D2021-08-25Director30k
Patel (Ashish R)Acquisition at price 4.38 per share.D2021-08-20Promoter26k
Patel (Munjal M)Acquisition at price 4.48 per share.D2021-08-20Promoter30k
Patel (Ashish R)Acquisition at price 4.55 per share.D2021-08-13Additonal Director15k
Patel (Munjal M)Acquisition at price 4.55 per share.D2021-08-13Director35k
Patel (Munjal M)Acquisition at price 4.29 per share.D2021-06-28Director50k
Shah (Shivani B)Purchase at price 4.17 per share.D2021-06-24UNREPORTED4.47k
Patel (Munjal M)Acquisition at price 4.27 per share.D2021-06-16Director50k
Patel (Munjal M)Acquisition at price 3.05 per share.D2021-03-19Director20k
Patel (Munjal M)Acquisition at price 3.10 per share.D2021-02-26Director36k
Patel (Anirudhh Hasmukhbhai)Acquisition at price 3.21 per share.D2021-02-25UNREPORTED17.5k
Patel (Jigar Hasmukhbhai)Acquisition at price 3.21 per share.D2021-02-25Promoter17.5k
Patel (Munjal M)Acquisition at price 3.21 per share.D2021-02-25Director40k
Patel (Ashish R)Acquisition at price 3.10 per share.D2021-02-23Additonal Director26k
Patel (Ashish R)Acquisition at price 3.09 per share.D2021-02-22Additonal Director30k
Patel (Ashish R)Acquisition at price 3.09 per share.D2021-02-19Additonal Director60k
Patel (Ashish R)Acquisition at price 3.00 per share.D2021-02-17Additonal Director64k
Patel (Ashish R)Acquisition at price 3.02 per share.D2021-02-16Additonal Director25k
Patel (Munjal M)Acquisition at price 3.04 per share.D2021-02-16Director37.5k
Patel (Anand Arvindbhai)Acquisition at price 3.09 per share.D2021-02-15Promoter50k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to LINCOLN PHARMA LTD. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on LINCOLN PHARMA LTD

Here is the result of two systematic investment strategies applied to LINCOLN PHARMA LTD. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on LINCOLN PHARMA LTD

The following chart shows the equity curve of the two systematic investment strategies applied to LINCOLN PHARMA LTD:

LINCOLN PHARMA LTD automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 29.97% on the backtest period.

Performance at glance

Performance

29.97 %

Latent gain

785.5 ₹

Invested capital

2620.7 ₹

Annualized return

7.1 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on LINCOLN PHARMA LTD

This is the result of two momentum investment strategies applied to LINCOLN PHARMA LTD. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on LINCOLN PHARMA LTD

The following chart shows all the entries opened by the momentum investment system on LINCOLN PHARMA LTD:

LINCOLN PHARMA LTD momentum entries
  • The first momentum investment strategy would give 36.72% of return on LINCOLN PHARMA LTD. That represents 2134.75₹ of latent gain with 5813.05₹ of employed capital.
  • The second momentum investment strategy would give 40.28% of return on LINCOLN PHARMA LTD. That represents 1467.1₹ of latent gain with 3642.2₹ of employed capital.
Performance at glance (1Q Momentum)

Performance

36.72 %

Latent gain

2134.75 ₹

Invested capital

5813.05 ₹

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

40.28 %

Latent gain

1467.1 ₹

Invested capital

3642.2 ₹

Annualized return

10.77 %

Momentum equity curve on LINCOLN PHARMA LTD

The following chart shows the equity curve of the two momentum strategies applied to LINCOLN PHARMA LTD:

LINCOLN PHARMA LTD momentum equity

Note: the dividends potentially given by LINCOLN PHARMA LTD are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on LINCOLN PHARMA LTD

The following chart shows the employed capital evolution of the two momentum strategies on LINCOLN PHARMA LTD since the beginning:

LINCOLN PHARMA LTD

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250₹, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000₹.


Buy the dip strategy result on LINCOLN PHARMA LTD

Buy the dip entry openings on LINCOLN PHARMA LTD

LINCOLN PHARMA LTD

The performance achieved by the robo-advisor on LINCOLN PHARMA LTD is 0%. That represents 0.0$ of latent gain with 0.0₹ of employed capital. The following chart shows LINCOLN PHARMA LTD stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of LINCOLN PHARMA LTD, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 ₹

Invested capital

0.0 ₹

Annualized return

0.0 %

Equity curve of the strategy applied to LINCOLN PHARMA LTD

The following chart shows the result of the investment strategy applied to LINCOLN PHARMA LTD:

LINCOLN PHARMA LTD

Note: the dividends potentially given by LINCOLN PHARMA LTD are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on LINCOLN PHARMA LTD

The following chart shows the employed capital evolution since the beginning of the investment strategy on LINCOLN PHARMA LTD:

LINCOLN PHARMA LTD

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on LINCOLN PHARMA LTD

In this section, I will compare the three previous investment strategies applied to LINCOLN PHARMA LTD.

Equity curve comparison on LINCOLN PHARMA LTD

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

LINCOLN PHARMA LTD investment strategy comparison

Employed capital comparison on LINCOLN PHARMA LTD

LINCOLN PHARMA LTD investment comparison

Performance comparison on LINCOLN PHARMA LTD

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 29.97% 785.5₹ 2620.7₹ 7.1%
Momentum 1 quarter 36.72% 2134.75₹ 5813.05₹ 9.23%
Momentum 2 quarters 40.28% 1467.1₹ 3642.2₹ 10.77%
Non-directional 0% 0.0₹ 0.0₹ 0.0%
Annualized return comparison

Automatic investment

7.1 %

Momentum 1Q

10.77 %

Momentum 2Q

10.77 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with LINCOLN PHARMA LTD:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between LINCOLN PHARMA LTD and the other stocks. There may be false positives or some missing correlated stocks. If the price of LINCOLN PHARMA LTD does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name LINCOLN PHARMA LTD
Country India
City Ahmedabad
Address Lincoln House
Phone 91 79 4107 8000
Website www.lincolnpharma.com
FullTime employees
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XNSE
Ticker LINCOLN.XNSE
Market

LINCOLN PHARMA LTD ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown